Prospective Observational Study to Estimate the Genotype and Phenotype of Japanese Patients With X-linked Retinitis Pigmentosa Associated With Pathogenic Variants in Retinitis Pigmentosa GTPase Regulator (RPGR)

Janssen Pharmaceutical K.K.1 site in 1 country15 target enrollmentJuly 26, 2021

ConditionsX-Linked Retinitis Pigmentosa

Overview

Phase: Not Applicable
Intervention: Not specified
Conditions: X-Linked Retinitis Pigmentosa
Sponsor: Janssen Pharmaceutical K.K.
Enrollment: 15
Locations: 1
Primary Endpoint: Visual Function
Status: Completed
Last Updated: last year

Overview Investigators Eligibility Criteria Outcomes Sites Similar Trials

Overview

Brief Summary

The purpose of the study is to identify a cohort of Japanese participants with X-linked retinitis pigmentosa (XLRP) associated with pathogenic variants in the retinitis pigmentosa GTPase regulator (RPGR) gene and to investigate their associated phenotype.

Registry

clinicaltrials.gov

Start Date

July 26, 2021

End Date

April 23, 2024

Last Updated

last year

Study Type

Observational

Sex

All

Investigators

Sponsor

Janssen Pharmaceutical K.K.

Responsible Party

Sponsor

Eligibility Criteria

Inclusion Criteria

•Have RPGR-associated retinal dystrophy
•Are able to give informed consent or assent, with the guidance of their parent/guardian where appropriate
•Are able to undertake age-appropriate clinical assessments as specified in the protocol

Exclusion Criteria

•Are unable or unwilling to undertake consent or clinical testing
•Participated in another research study and had intraocular surgery within 3 months of screening
•Significant ophthalmologic diseases